A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity

Cancer Research

Volumn 66, Issue 18, 2006, Pages 9171-9177

  Aggarwal, Saurabh ^a   Singh, Pratap ^b   Topaloglu, Ozlem ^a   Isaacs, John T ^a,b   Demneade, Samuel R ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Johns Hopkins University   (United States)

^c Bunting Blaustein Cancer Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CARBOXYPEPTIDASE; HISTIDINE; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANTIGEN BINDING; ARTICLE; CANCER CELL; DIMERIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CANCER;

AMINO ACID SEQUENCE; ANTIGENS, SURFACE; CELL LINE, TUMOR; DIMERIZATION; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MODELS, MOLECULAR; OLIGOPEPTIDES; PEPTIDE LIBRARY; PROSTATIC NEOPLASMS; PROTEIN BINDING; SUBSTRATE SPECIFICITY;

EID: 33749461961     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1520     Document Type: Article

References (40)

1. Fair WR, Israeli RS, Heston WD. Prostate-specific membrane antigen. Prostate 1997;32:140-8.
2. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997;57:2321-4.
3. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
4. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-601.
5. Mhaka A, Gady AM, Rosen DM, et al. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA). Cancer Biol Ther 2004;3:551-8.
6. Davis MI, Bennett MJ, Thomas LM, et al. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A 2005;102:5981-6.
7. Schulke N, Varlamova OA, Donovan GP, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A 2003;100:12590-5.
8. O'Keefe DS, Bacich DJ, Heston WD. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate 2004;58:200-10.
9. Cunha AC, Weigle B, Kiessling A, et al. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006;236:229-38.
10. Dumas F, Gala JL, Berteau P, et al. Molecular expression of PSMA mRNA and protein in primary renal tumors. Int J Cancer 1999;80:799-803.
11. Gala JL, Loric S, Guiot Y, et al. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin Cancer Res 2000;6:4049-54.
12. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-34.
13. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
14. Huang X, Bennett M, Thorpe PE. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 2004;61:1-11.
15. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003;170: S84-8; discussion S88-9.
16. Leuschner C, Enright FM, Gawronska-Kozak B, et al. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate 2003;56:239-49.
17. Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003;72:2305-20.
18. Grifman M, Trepel M, Speece P, et al. Incorporation of tumor-targeting peptides into recombinant adenoassociated virus capsids. Mol Ther 2001;3:964-75.
19. Barbas CF, Burton DR, Scott JK, Silverman GJ. Phage display: a laboratory manual. Cold Spring Harbor (New York): Cold Spring Harbor Laboratory Press; 2000.
20. Aggarwal S, Janssen S, Wadkins RM, et al. A combinatorial approach to the selective capture of circulating malignant epithelial cells by peptide ligands. Biomaterials 2005;26:6077-86.
21. Tiffany CW, Lapidus RG, Merion A, et al. Characterization of the enzymatic activity of PSM: comparison with brain NAALADase. Prostate 1999;39:28-35.
22. Gebhardt K, Lauvrak V, Babaie E, et al. Adhesive peptides selected by phage display: characterization, applications and similarities with fibrinogen. J Pept Res 1996;9:269-78.
23. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997;276:1696-9.
24. Wrighton NC, Balasubramanian P, Barbone FP, et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat Biotechnol 1997;15:1261-5.
25. Luthi-Carter R, Barczak AK, Speno H, et al. Molecular characterization of human brain N-acetylated α-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 1998;286:1020-5.
26. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A 1996;93:749-53.
27. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-51.
28. 2 terminus of ubiquitin. Conformational preferences of β-turn residues dictate non-native β-strand interactions. Eur J Biochem 2000;267:3539-48.
29. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002;8:121-7.
30. El-Mousawi M, Tchistiakova L, Yurchenko L, et al. A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library. J Biol Chem 2003;278:46681-91.
31. Pan W, Arnone M, Kendall M, et al. Identification of peptide substrates for human MMP-11 (stromelysin-3) using phage display. J Biol Chem 2003;278:27820-7.
32. Smith GP, Petrenko VA. Phage display. Chem Rev 1997;97:391-410.
33. Aina OH, Sroka TC, Chen ML, et al. Therapeutic cancer targeting peptides. Biopolymers 2002;66:184-99.
34. Menendez A, Scott JK. The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies. Anal Biochem 2005;336:145-57.
35. Lupold SE, Rodriguez R. Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. Mol Cancer Ther 2004;3:597-603.
36. Dreier B, Segal DJ, Barbas CF III. Insights into the molecular recognition of the 5′-GNN-3′ family of DNA sequences by zinc finger domains. J Mol Biol 2000;303:489-502.
37. Eteshola E, Brillson LJ, Lee SC. Selection and characteristics of peptides that bind thermally grown silicon dioxide films. Biomol Eng 2005;22:201-4.
38. Rodi DJ, Soares AS, Makowski L. Quantitative assessment of peptide sequence diversity in M13 combinatorial peptide phage display libraries. J Mol Biol 2002;322:1039-52.
39. Lannom HK, Dill K, Denarie M, et al. 13C n.m.r. study of the structure and the metal ion binding sites of neuropeptides composed of L-Asp and L-Glu. Int J Pept Protein Res 1986;28:67-78.
40. Oliver AJ, Wiest O, Helquist P, et al. Conformational and SAR analysis of NAALADase and PSMA inhibitors. Bioorg Med Chem 2003;11:4455-61.